Celtaxsys banks $45M for its cystic fibrosis drug

Atlanta-headquartered biotech Celtaxsys raised $45 million in Series D cash, plotting to kick off a Phase II study for its lead drug, an anti-inflammatory treatment for cystic fibrosis. The round, led by Domain Partners, gives Celtaxsys the funds it needs to advance CTX-4430, an oral drug designed to preserve lung function in CF patients. The company is also earmarking cash to complete an ongoing Phase II acne study. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.